Actively Recruiting
Predicting Response to Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer Using Genetic and Molecular Analysis
Led by Yonsei University · Updated on 2024-04-18
250
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating how to better predict which patients with muscle-invasive bladder cancer will respond well to neoadjuvant chemotherapy. This study focuses on analyzing genetic and molecular profiles from tumor tissues obtained through transurethral bladder tumor resection to identify those likely to benefit from chemotherapy. The goal is to tailor treatment more effectively, avoiding unnecessary toxicity and delays for patients unlikely to respond, and guiding them toward alternative treatments such as radical cystectomy. Participants in this observational study receive platinum-based neoadjuvant chemotherapy, either with a combination of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin ddMVAC or a combination of gemcitabine and cisplatin GC, followed by radical cystectomy surgery. Patients are grouped based on whether they have a favorable or unfavorable response to chemotherapy as determined by their genetic and molecular tumor profiles. During the study, researchers collect tumor tissue samples at the time of bladder tumor resection to analyze genetic and molecular markers. The primary goal is to identify responders after two cycles of chemotherapy. Long-term outcomes such as overall survival, cancer-specific survival, progression-free survival, and recurrence-free survival will be monitored for up to 10 years following chemotherapy and surgery. Participants are expected to be actively involved by providing tissue samples and consenting to follow-up assessments over time.
CONDITIONS
Brief Title
Prediction of Therapeutic Response to Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer Patients Using Spatial Transcriptomics
Research Team
W
Won Sik Ham
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here